Phase I - Serological Assays for the detection and characterization of influenza viruses
Closed Solicitation Posted
Not the latest version. See the latest pre-solicitation from .
- Solicitation number
- 75D30125R73211_Phase_I
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- Total Small Business
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Atlanta, Georgia, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) Office of Acquisition Services is soliciting competitive bids from small businesses for a contract to provide serological assay testing services and develop a new serology platform for the CDC Influenza Division. The contractor will conduct hemagglutination inhibition (HAI) assays on approximately 6,000 human samples per year, with optional surge levels of 9,000 or 10,500 samples. The contract also includes optional tasks for the contractor to design, validate, and deliver an improved serology assay comparable to HAI. The Government will provide the HAI testing protocol, positive and negative controls, proficiency panels, and human samples. The contract will be a mix of firm-fixed-price and cost-plus-fixed-fee pricing.
This opportunity is set aside for small businesses under NAICS code 325413 "In-Vitro Diagnostic Substance Manufacturing" with a size standard of 1,250 employees. The contract has a one-year base period and four one-year option periods. The place of performance is Atlanta, GA. The solicitation is posted on November 14, 2024, and proposals are due by November 21, 2024.
Notice text
The objective of this contract is to support the Influenza Division through the testing of human sera via hemagglutination inhibition assay as well as develop a new serology platform that is comparable to hemagglutination inhibition assay.
Files
| File | Type | Posted |
|---|---|---|
| A19_75D301-25-R-73211.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Phase I - Serological Assays for the detection and characterization of influenza viruses | Pre-Solicitation | |
| This notice | Solicitation | |
| Serological Assays for the detection and characterization of influenza viruses | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Safety, Prevention, Epidemiology, and Education Development for Health Care and Antimicrobial Resistance - SPEED 2027-2032 | CDC Office of Acquisition Services | Partial Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity